UCB's CIMZIA Receives FDA Breakthrough Therapy Designation In Pregnant Women With APS

UCB SA (UCBJY), announced that the U.S. FDA has granted Breakthrough Therapy Designation to CIMZIA (certolizumab pegol) for the prevention of placenta-mediated adverse pregnancy outcomes in pregnant women with antiphospholipid syndrome (APS) who are positive for lupus anticoagulant.